title: Programmable infusion pump and catheter: evaluation using 3-tesla magnetic resonance imaging.
abstract: Objective.  This study assessed 3-Tesla magnetic resonance imaging (MRI) issues for a programmable infusion pump and associated catheters. Methods.  A programmable infusion pump and associated catheters (MedStream Programmable Infusion Pump, 40 mL; SureStream TI Coil-Reinforced Intraspinal Catheter; SureStream TI Connector; and SureStream Silicone Catheter; Codman and Shurtleff Inc., a Johnson & Johnson Company, Raynham, MA, USA) underwent evaluation for magnetic field interactions (deflection angle and torque), heating (transmit/receive body radiofrequency coil; whole-body averaged specific absorption rate, 3 W/kg for 15 min), functional changes (before and after MRI using eight different MRI conditions), and artifacts (T1-weighted spin-echo and gradient-echo pulse sequences) at 3-Tesla. Results.  The programmable infusion pump and associated catheters exhibited minor magnetic field interactions. Heating was not excessive (≤ 1.9°), especially considering the experimental conditions used for this evaluation (ie, relatively high radiofrequency power/specific absorption rate level and use of a nonperfused phantom). The function of three out of six pumps was temporarily altered by exposures to 3-Tesla MRI conditions. Reset was achieved in each case. Artifacts were relatively large for the pump and minor for the catheter. Conclusions.  The programmable infusion pump and catheters will not pose increased risk to a patient examined using 3-Tesla MRI as long as specific safety guidelines are followed, which includes interrogation of the pump post-MRI to ensure proper settings. Artifacts for the programmable infusion pump may impact the diagnostic use of MRI if the area of interest is in the same area or near the device.
authors.affiliation: Keck School of Medicine, University of Southern California and Institute for Magnetic Resonance Safety, Education, and Research, Los Angeles, CA, USA;              Codman Neurosciences, a Johnson & Johnson Company, Le Locle, Switzerland; and              Codman and Shurtleff Inc., a Johnson & Johnson Company, Raynham, MA, USA.
authors.forename: Frank G
authors.initials: FG
authors.lastname: Shellock
authors.forename: Rocco
authors.initials: R
authors.lastname: Crivelli
authors.forename: Ramakrishna
authors.initials: R
authors.lastname: Venugopalan